Also
- Share via
MedImmune Inc. and partner Wyeth said they would end their agreement to develop the FluMist nasal spray influenza vaccine, which failed to catch on with consumers in its first year on the market. MedImmune will proceed on its own to develop a new version of the vaccine.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
